Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved ...

Black men who were identified as sexual minorities were more receptive to long-acting injectable pre-exposure prophylaxis ...

Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being ...

The Braidwood decision maintains the status quo for many patients, keeping preventive services covered by Medicaid under the ...

Panelists discuss how patient financial burden varies significantly by insurance type and often leads to treatment ...

Panelists discuss how healthcare resource utilization is primarily driven by hospitalizations, medication costs, and ...

Alexander I. Spira, MD, PhD, of The US Oncology Network, discusses findings from the COCOON trial that show prophylactic ...

The finding that basophil counts may have prognostic significance aligns with a growing body of research into basophils in ...

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

The post hoc analysis of the AGAVE-201 trial found that axatilimab demonstrated consistent response rates in patients with chronic graft-vs-host disease (GVHD), regardless of the number or type of ...

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable ...

There are significant racial disparities in outpatient referrals for opioid use disorder treatment, highlighting urgent need for targeted interventions in emergency care, according to a recent study.